下一代肿瘤“药王”争夺战打响!撰文丨粽哥2025下一代肿瘤“药王”,极有可能诞生于PD-(L)1+X领域。以K药为代表的PD-1单抗,开启了一代IO(肿瘤免疫)治疗时代,但却存在耐药和冷肿瘤缺乏应答的问题。这些临床痛点,催生了在PD-1基础上进阶的PD-(L)1+X药物,并凭借多靶点结合提升疗效、降低毒性、拓展适用人群等优势,开启了二代IO时代。巨大的潜力让二代IO药物迅速成为市场焦点,其中热门...
Source Link下一代肿瘤“药王”争夺战打响!撰文丨粽哥2025下一代肿瘤“药王”,极有可能诞生于PD-(L)1+X领域。以K药为代表的PD-1单抗,开启了一代IO(肿瘤免疫)治疗时代,但却存在耐药和冷肿瘤缺乏应答的问题。这些临床痛点,催生了在PD-1基础上进阶的PD-(L)1+X药物,并凭借多靶点结合提升疗效、降低毒性、拓展适用人群等优势,开启了二代IO时代。巨大的潜力让二代IO药物迅速成为市场焦点,其中热门...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.